Skip to content
sellWeak cluster of 2

Benjamin Hickey sold $94k of MRTX

EVP, Chief Commercial Officer at Mirati Therapeutics, Inc.. 1,597 shares at an average of $59.02, traded Jan 16, 2024, filed Jan 18, 2024.

Warning score
33
Value
$94k
1,597 shares
Holdings after
117,028
-1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Officer
    +15
  • Trade size
    $94k at market
    +10
  • Share of holdings sold
    Sold 1.3% of holdings
    0
  • Cluster
    2 insiders selling within 14 days
    +8

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0001628280-24-001696, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jan 16, 2024SOpen-market sale
Common Stock
-966$59.02$57k117,659Jan 18, 2024
Jan 16, 2024SOpen-market sale
Common Stock
-631$59.02$37k117,028Jan 18, 2024

Related signals

Other insiders at Mirati Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
33Weak
MRTXsell 2
Mirati Therapeutics, Inc.
Jamie Christensen
EVP & Chief Scientific Officer
$94k
1,597 shares
-1%
33Weak
MRTXsell 2
Mirati Therapeutics, Inc.
Benjamin Hickey
EVP, Chief Commercial Officer
$123k
2,090 shares
-2%
32Weak
MRTXsell 2
Mirati Therapeutics, Inc.
Jamie Christensen
EVP & Chief Scientific Officer
$90k
1,531 shares
-1%
34Weak
MRTXsell 2
Mirati Therapeutics, Inc.
Jamie Christensen
EVP & Chief Scientific Officer
$137k
2,387 shares
-2%
34Weak
MRTXsell 2
Mirati Therapeutics, Inc.
Benjamin Hickey
EVP, Chief Commercial Officer
$126k
2,220 shares
-2%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Benjamin Hickey sold $94k of MRTX | InsiderTell